EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis

Ju Heon Park, Sejin Oh, Jihye Park, YoungHwan Choi iD, Jong Hee Lee iD

Journal of Clinical Medicine · 17.06.2025 · 14 (12) · 4312

DOI: 10.3390/jcm14124312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.06.2025. Verfasst von Ju Heon Park und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul 06351, Republic of Korea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Numerous novel medications are being developed to treat moderate to severe atopic dermatitis (AD), notably biologics and Janus kinase inhibitors (JAKis). However, the exact guideline for the first determination of which medication has not been established yet. This study was conducted to identify patients who would show favorable clinical results from using JAKis.

Methods

Based on the degree of improvement in EASI at 16 weeks, 43 patients were divided into three groups: Group 1 (EASI-90), Group 2 (EASI-75), and Group 3 (EASI-50).

Results

Compared to Group 1 and Group 2, Group 3 exhibited a significantly higher rate of multiple positive results in MAST (p-value = 0.005, p-value = 0.004), a greater proportion of individuals with higher IgE levels exceeding 1000 (p-value = 0.003, p-value = 0.027), and the presence of allergic comorbidities (p-value = 0.049, p-value = 0.026). However, baseline laboratory test results, such as eosinophil counts, LDH, and so on, showed no significant differences among the three groups.

Conclusions

JAKis might provide prompt clinical improvement, especially in patients with relatively low serum Ig E levels who do not have multiple allergen positivities and allergic comorbidities.

Schlagwörter

Stichwörter der Autor:innen

Janus kinase inhibitorsatopicbiological productsdermatitisimmunoglobulin E

Autor:innen und Institutionen

  • Department of Dermatology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul 06351, Republic of Korea.
  • Department of Medical Device Management & Research, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06355, Republic of Korea.
  • New Drug Development Division, ENCell Corp, Seoul 05854, Republic of Korea.

ORCID-Profile: YoungHwan Choi, Jong Hee Lee

Zitieren

APA

Park, J. H., Oh, S., Park, J., Choi, Y., & Lee, J. H. (2025). Predicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis. Journal of Clinical Medicine, 14(12), 4312. https://doi.org/10.3390/jcm14124312

Vancouver

Park JH, Oh S, Park J, Choi Y, Lee JH. Predicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis. Journal of Clinical Medicine. 2025;14(12):4312. doi:10.3390/jcm14124312

BibTeX
@article{Park2025,
  author = {Park, Ju Heon and Oh, Sejin and Park, Jihye and Choi, YoungHwan and Lee, Jong Hee},
  title = {Predicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {12},
  pages = {4312},
  doi = {10.3390/jcm14124312}
}
Kostenlos starten →